一体化布局成效渐显 美诺华去年净利润增长476.64%

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. reported a significant increase in revenue and net profit for the year 2024, driven by its integrated strategy in the pharmaceutical sector and strong performance in its formulation business [1][2]. Group 1: Financial Performance - The company achieved an operating income of 1.373 billion yuan, representing a year-on-year growth of 12.85% [1]. - The net profit attributable to shareholders reached 66.81 million yuan, marking a substantial increase of 476.64% compared to the previous year [1]. Group 2: Business Strategy and Market Position - Meinuo has focused on building robust partnerships with multinational pharmaceutical companies, leveraging its experience with European clients to enhance its business model [1]. - In 2024, overseas business accounted for 69.77% of total revenue, with European business making up 81.88% of the overseas segment [1]. - The formulation business saw a remarkable revenue increase of 83.52%, becoming the core driver of the company's revenue growth [1][2]. Group 3: Research and Development Focus - The company concentrated its R&D efforts on chronic disease treatment, aiming to overcome technical and patent barriers [2]. - Meinuo has developed multiple technology platforms, including sustained-release and solubility enhancement technologies, to create high-value products with significant market potential [2]. Group 4: Market Strategy - The company adopts a market strategy primarily focused on centralized procurement, while also exploring new channels such as grassroots medical markets, retail pharmacies, and e-commerce platforms [2]. - In 2024, several products, including Perindopril and Moxifloxacin tablets, successfully won bids in multiple provinces [2]. Group 5: Raw Material Business - Despite facing challenges such as rising raw material costs, the raw material business still achieved a revenue growth of 6.10% [2]. Group 6: Industry Insights - Industry experts highlight Meinuo's advantages in raw material quality and scale, which contribute to effective cost control and quality management in the formulation sector [3]. - The company's participation in centralized procurement has expanded its market coverage and increased its market share, leading to stable revenue growth [3].